Biocon Limited · NSE:BIOCON
Biocon — 44th Annual J.P. Morgan Healthcare Conference (January 2026)
20 slides from Biocon's conference presentation, Jan 15, 2026
Slide 1: Making Lifesaving Medicines Affordable and Accessible to Patients Everywhere
Making Lifesaving Medicines Affordable and Accessible to Patients Everywhere Shreehas Tambe CEO & Managing Director January 15, 2026
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation has been prepared by Biocon Limited (the “Company”). It is not the intention to provide, and you may not rely on this presentation as providing, a complete or comprehensive analysis of the Company’s or its affiliates business, financial condition, results of o
Slide 3: We are Biocon
We are Biocon
Slide 4: Biocon Group – A Leading Global Biopharmaceutical Company
Biocon Group – A Leading Global Biopharmaceutical Company Improving patients' lives by delivering affordable healthcare products and differentiated services 47+ Global reach in Market cap of $ 1,806M 215+ 14 of Top 20 1,500+ 11 year legacy 120+ In Revenues cGMP Pharma companies Patents1 Manufacturin
Slide 5: Our Aspiration
Our Aspiration Leveraging science and innovation to make life-saving medicines affordable and accessible to patients 2004 2017 2025 2021 Launched India’s first Commercialized first Received approval and Commercialized the first recombinant human insulin, biosimilar Trastuzumab in commercialized the
Slide 6: Our Transformative Journey over the Years
Our Transformative Journey over the Years Early pioneers of biotech democratizing access to chronic and life-saving therapies globally Enzymes Transforming into Biosimilars Global Company Biopharma Scale-Up Reach 1978 1998 2009 2019 2022 Acquired Viatris’ Carved out Biocon Biologics Biocon forayed i
Slide 7: Next Phase: Integration of Biocon Limited and Biocon Biologics
Next Phase: Integration of Biocon Limited and Biocon Biologics Combining our Generics and Biosimilar businesses will unlock value for patients, prescribers, customers and shareholders Present Day Strategic Differentiators of Combined Business Generics (API, GLPs, OSDs, Injectables) Research & Manufa
Slide 8: Rationale for Integration of Biocon Limited and Biocon Biologics
Rationale for Integration of Biocon Limited and Biocon Biologics Consolidation simplifies structure, improves financial metrics, and unleashes combined potential of the two businesses Simplified corporate Operating synergies & improved Cross-leverage portfolio & structure capital allocation commerci
Slide 9: Our Impact
Our Impact
Slide 10: Evolving Global Disease Burden
Evolving Global Disease Burden Shift in global disease burden from communicable diseases to non-communicable diseases (NCD’s) Oncology Total Disease Burden by Total Disease Burden by Cause (Billion DALYs*) Cause (Billion DALYs*) Incidence expected to increase to 35M new patients annually by 2050. 77
Slide 11: Differentiated Portfolio focused on High-Need Therapy Areas
Differentiated Portfolio focused on High-Need Therapy Areas Combined portfolio includes biosimilars, insulins, GLPs and complex generics Biosimilars Generics Examples Approved Pipeline Pertuzumab Trastuzumab SC Pegfilgrastim Denosumab Dasatinib Oncology Pembrolizumab Palbociclib Trastuzumab Bevacizu
Slide 12: State-of-the-art Manufacturing Facilities
State-of-the-art Manufacturing Facilities 300+ KL Drug substance manufacturing capacity | 100M + units injectable manufacturing capacity | 2Bn + oral solid capacity Drug Substance Drug Product R&D mAbs Fermentation Synthetic Injectables OSD Bengaluru Biologics Manufacturing R&D Chennai R&D Joh
Slide 13: Strong Commercial Capabilities with Global Footprint
Strong Commercial Capabilities with Global Footprint Expanding our commercial footprint globally through diverse GTM models Combined entity presence Commercial Models Mix of both self-led markets and partnered markets 29 90+ 358+ self-led partnered employees markets markets Presence across Tender, R
Slide 14: Existing Portfolio holds Significant Market Share
Existing Portfolio holds Significant Market Share Direct presence across major countries and a network of established partners and distributors Biologics Business- Advanced Markets Generic Formulations – Advanced Markets Market share Q3 CY2024 Q3 CY2025 Q3 CY2024 Q3 CY2025 23% 25% 22% 23% 49% 57% 50
Slide 15: Strong Launch Momentum going into 2026
Strong Launch Momentum going into 2026 Multiple global launches lined-up across oncology, immunology and GLP-1s in 2026 Successfully launched Oncology and Immunology Launches Insulin Launch GLP Launches Semaglutide Addressable Market* >> $8 B $5 B $7 B $11 B $3 B $2 B $29 B U.S. U.S. U.S. U.S. U.S.
Slide 16: Robust Mid-Term Pipeline with Continued Focus on High Value Areas
Robust Mid-Term Pipeline with Continued Focus on High Value Areas By addressing 2/3rd of Biologics market going off-patent by 2031, our pipeline is built to unlock affordable access for patients globally 16 in early to mid-stage • USD ~135 Bn of Oncology + Addressable market1 Immunology • Molecule C
Slide 17: Strong Financial Performance in Biosimilar Business
Strong Financial Performance in Biosimilar Business Positive financial growth trajectory post Viatris acquisition Highlights Key Financials2 Preserve Consolidate Accelerate Revenue reflects steady growth 1,044 1,067 USDmn Revenue 613 Continued EBITDA margin expansion reflecting operating leverage be
Slide 18: Successful Corporate Actions to Strengthen Balance Sheet
Successful Corporate Actions to Strengthen Balance Sheet We have embarked on a comprehensive journey to improve our financial metrics (Sep- Oct 2024) (May – June 2025) (Dec - Jan 2026) Acquisition Loan Refinancing QIP for Redemption of Business Integration Structured Instruments Refinancing through
Slide 19: Key Leadership Team Members – Combined Business
Key Leadership Team Members – Combined Business Leadership team with proven track record to lead the next phase of growth MATTHEW ERICK KEDAR UPADHYE Chief Commercial Officer KIRAN Chief Financial Officer – Advanced Markets MAZUMDAR-SHAW Executive Chairperson SUSHEEL UMESH RHONDA DUFFY Chief Commerc
Slide 20: Thank You
Thank You ACCELERATING REACH Propelli ing Growth,
Biocon — 44th Annual J.P. Morgan Healthcare Conference (January 2026) on 6ix